Use of multiparametric magnetic resonance imaging and fusion-guided biopsies to properly select and follow African-American men on active surveillance.
#PCSM
#ProstateCancer
African-American
active surveillance
fusion biopsy
multi-parametric MRI
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
pubmed:
30
5
2019
medline:
2
6
2020
entrez:
30
5
2019
Statut:
ppublish
Résumé
To determine the rate of Gleason Grade Group (GGG) upgrading in African-American (AA) men with a prior diagnosis of low-grade prostate cancer (GGG 1 or GGG 2) on 12-core systematic biopsy (SB) after multiparametric magnetic resonance imaging (mpMRI) and fusion biopsy (FB); and whether AA men who continued active surveillance (AS) after mpMRI and FB fared differently than a predominantly Caucasian (non-AA) population. A database of men who had undergone mpMRI and FB was queried to determine rates of upgrading by FB amongst men deemed to be AS candidates based on SB prior to referral. After FB, Kaplan-Meier curves were generated for AA men and non-AA men who then elected AS. The time to GGG upgrading and time continuing AS were compared using the log-rank test. AA men referred with GGG 1 disease on previous SB were upgraded to GGG ≥3 by FB more often than non-AA men, 22.2% vs 12.7% (P = 0.01). A total of 32 AA men and 258 non-AA men then continued AS, with a median (interquartile range) follow-up of 39.19 (24.24-56.41) months. The median time to progression was 59.7 and 60.5 months, respectively (P = 0.26). The median time continuing AS was 61.9 months and not reached, respectively (P = 0.80). AA men were more likely to be upgraded from GGG 1 on SB to GGG ≥3 on initial FB; however, AA and non-AA men on AS subsequently progressed at similar rates following mpMRI and FB. A greater tendency for SB to underestimate tumour grade in AA men may explain prior studies that have shown AA men to be at higher risk of progression during AS.
Identifiants
pubmed: 31141307
doi: 10.1111/bju.14835
pmc: PMC8288555
mid: NIHMS1032594
doi:
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
768-774Subventions
Organisme : Intramural NIH HHS
ID : Z01 BC010655
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA BC011081
Pays : United States
Organisme : Intramural NIH HHS
ID : ZID BC011242
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIE SC000853
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 The Authors BJU International © 2019 BJU International Published by John Wiley & Sons Ltd.
Références
Clin Cancer Res. 2014 Sep 15;20(18):4925-34
pubmed: 25056375
BJU Int. 2014 Dec;114(6b):E43-E49
pubmed: 24712649
J Urol. 2011 Oct;186(4):1281-5
pubmed: 21849184
J Clin Oncol. 2015 Oct 20;33(30):3379-85
pubmed: 26324359
J Urol. 2017 Feb;197(2):342-349
pubmed: 27596691
J Clin Oncol. 2015 Jan 20;33(3):272-7
pubmed: 25512465
Urology. 2015 Jan;85(1):155-60
pubmed: 25440814
J Urol. 2012 May;187(5):1594-9
pubmed: 22425088
Prostate Cancer Prostatic Dis. 2017 Jun;20(2):127-136
pubmed: 28417980
J Urol. 2014 Jan;191(1):60-7
pubmed: 23770146
Oncology (Williston Park). 2014 Jan;28(1):83, 85
pubmed: 24683725
Cancer Causes Control. 2012 Jul;23(7):1185-91
pubmed: 22674292
Urology. 2016 May;91:143-9
pubmed: 26944351
Cancer Discov. 2017 Sep;7(9):973-983
pubmed: 28515055
JAMA. 2018 Dec 18;320(23):2479-2481
pubmed: 30561471
Radiology. 2010 Apr;255(1):89-99
pubmed: 20308447
Prostate Cancer Prostatic Dis. 2013 Mar;16(1):85-90
pubmed: 23069729
J Urol. 2017 Mar;197(3 Pt 1):627-631
pubmed: 27582435
Eur Urol. 2019 Jun;75(6):1038-1040
pubmed: 30683576
Eur Urol. 2015 Mar;67(3):451-7
pubmed: 24746973
Cancer. 2013 Jun 15;119(12):2223-9
pubmed: 23559420
JAMA. 2015 Jul 7;314(1):80-2
pubmed: 26151271
Urology. 2014 Feb;83(2):364-8
pubmed: 24286600
Cancer. 2017 Nov 1;123(21):4122-4129
pubmed: 28662291
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
JAMA. 2015 Jan 27;313(4):390-7
pubmed: 25626035
Curr Urol Rep. 2017 Aug 14;18(10):81
pubmed: 28808871
J Clin Oncol. 2013 Aug 20;31(24):2991-7
pubmed: 23775960
J Urol. 2016 Nov;196(5):1408-1414
pubmed: 27352635